These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25692975)

  • 1. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo.
    Matsumoto M; Tatematsu M; Nishikawa F; Azuma M; Ishii N; Morii-Sakai A; Shime H; Seya T
    Nat Commun; 2015 Feb; 6():6280. PubMed ID: 25692975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the Toll-like receptor 3 pathway in endosomal signaling.
    Matsumoto M; Funami K; Tatematsu M; Azuma M; Seya T
    Methods Enzymol; 2014; 535():149-65. PubMed ID: 24377923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA.
    Perrot I; Deauvieau F; Massacrier C; Hughes N; Garrone P; Durand I; Demaria O; Viaud N; Gauthier L; Blery M; Bonnefoy-Berard N; Morel Y; Tschopp J; Alexopoulou L; Trinchieri G; Paturel C; Caux C
    J Immunol; 2010 Aug; 185(4):2080-8. PubMed ID: 20639488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing.
    Seya T; Matsumoto M; Ebihara T; Oshiumi H
    Immunol Rev; 2009 Jan; 227(1):44-53. PubMed ID: 19120474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells.
    Akazawa T; Ebihara T; Okuno M; Okuda Y; Shingai M; Tsujimura K; Takahashi T; Ikawa M; Okabe M; Inoue N; Okamoto-Tanaka M; Ishizaki H; Miyoshi J; Matsumoto M; Seya T
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):252-7. PubMed ID: 17190817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral responses induced by the TLR3 pathway.
    Matsumoto M; Oshiumi H; Seya T
    Rev Med Virol; 2011 Mar; 21(2):67-77. PubMed ID: 21312311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
    Hafner AM; Corthésy B; Merkle HP
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells.
    McCartney S; Vermi W; Gilfillan S; Cella M; Murphy TL; Schreiber RD; Murphy KM; Colonna M
    J Exp Med; 2009 Dec; 206(13):2967-76. PubMed ID: 19995959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of TLR3 and its adaptor TICAM-1 increases miR-21 levels in extracellular vesicles released from human cells.
    Fukushima Y; Okamoto M; Ishikawa K; Kouwaki T; Tsukamoto H; Oshiumi H
    Biochem Biophys Res Commun; 2018 Jun; 500(3):744-750. PubMed ID: 29679565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 3-elicited MAPK activation induces stabilization of interferon-β mRNA.
    Johnsen IB; Nguyen TT; Bergstrøm B; Lien E; Anthonsen MW
    Cytokine; 2012 Mar; 57(3):337-46. PubMed ID: 22200507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a dendritic cell-targeting lipopeptide as an immunoadjuvant that inhibits tumor growth without inducing local inflammation.
    Akazawa T; Ohashi T; Nakajima H; Nishizawa Y; Kodama K; Sugiura K; Inaba T; Inoue N
    Int J Cancer; 2014 Dec; 135(12):2847-56. PubMed ID: 24789268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways.
    Miyake T; Kumagai Y; Kato H; Guo Z; Matsushita K; Satoh T; Kawagoe T; Kumar H; Jang MH; Kawai T; Tani T; Takeuchi O; Akira S
    J Immunol; 2009 Aug; 183(4):2522-8. PubMed ID: 19635904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination.
    Takeda Y; Takaki H; Fukui-Miyazaki A; Yoshida S; Matsumoto M; Seya T
    Biochem Biophys Res Commun; 2018 Dec; 506(4):1019-1025. PubMed ID: 30404733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7.
    Sugiyama T; Hoshino K; Saito M; Yano T; Sasaki I; Yamazaki C; Akira S; Kaisho T
    Int Immunol; 2008 Jan; 20(1):1-9. PubMed ID: 17981792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR3-mediated IFN-β gene induction is negatively regulated by the TLR adaptor MyD88 adaptor-like.
    Siednienko J; Halle A; Nagpal K; Golenbock DT; Miggin SM
    Eur J Immunol; 2010 Nov; 40(11):3150-60. PubMed ID: 20957750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-stranded RNA exacerbates pulmonary allergic reaction through TLR3: implication of airway epithelium and dendritic cells.
    Torres D; Dieudonné A; Ryffel B; Vilain E; Si-Tahar M; Pichavant M; Lassalle P; Trottein F; Gosset P
    J Immunol; 2010 Jul; 185(1):451-9. PubMed ID: 20505141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutting edge: priming of CD8 T cell immunity to herpes simplex virus type 1 requires cognate TLR3 expression in vivo.
    Davey GM; Wojtasiak M; Proietto AI; Carbone FR; Heath WR; Bedoui S
    J Immunol; 2010 Mar; 184(5):2243-6. PubMed ID: 20124105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.
    Seya T; Azuma M; Matsumoto M
    Expert Opin Ther Targets; 2013 May; 17(5):533-44. PubMed ID: 23414438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
    Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
    J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.